Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment of Orthostatic Hypotension
This study is currently recruiting participants.
Study NCT00581477   Information provided by Vanderbilt University
First Received: December 22, 2007   Last Updated: August 13, 2009   History of Changes

December 22, 2007
August 13, 2009
January 2004
December 2010   (final data collection date for primary outcome measure)
Change in blood pressure with standing [ Time Frame: following 5 days of medication ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00581477 on ClinicalTrials.gov Archive Site
length of time subject is able to stand [ Time Frame: following 5 days of medication ] [ Designated as safety issue: No ]
Same as current
 
Treatment of Orthostatic Hypotension
Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms

The purpose of this study is to try different medications in patients with low blood pressure and other problems with their involuntary (autonomic) nervous system. The pharmacological trials in this study will perhaps lead to more effective treatment. This study consists of single dose trials, dose selection trials, 5-day trials and chronic (approximately 2 months) trials.

We see many patients at the Autonomic Dysfunction Center who can be given a fairly definitive diagnosis, e.g., Orthostatic Intolerance, Pure Autonomic Failure, Multiple System Atrophy, and Baroreflex Failure. However, some patients present with a unique constellation of symptoms of autonomic dysfunction so that they do not fit into a diagnostic category. We hypothesize that a genetic cause exists in some of these patients. We further propose that our comprehensive evaluation of these patients will provide us with information on the pathophysiology of their condition and assist us in optimizing their treatment.

Phase III
Interventional
Treatment, Non-Randomized, Single Blind (Subject), Placebo Control, Crossover Assignment, Efficacy Study
  • Autonomic Nervous System Diseases
  • Orthostatic Hypotension
  • Drug: droxidopa
  • Drug: placebo
  • Drug: alpha-methyldopa
  • Drug: carbidopa
  • Drug: metyrosine
  • Drug: levodopa
  • Drug: atomoxetine
  • Drug: metoclopramide
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
25
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients with severe orthostatic hypotension and other autonomic symptoms who do not meet criteria for one of our standard diagnoses
  • non-smokers
  • drug-free
  • able to give informed consent
  • free of pulmonary, renal, hematopoietic, hepatic and cardiac disease

Exclusion Criteria:

  • medications affecting the autonomic nervous system
  • any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic)
  • anemia (Hct < 30)
  • women of childbearing age who are pregnant or nursing
  • smokers
Both
18 Years to 70 Years
No
Contact: Bonnie K Black, RN adc.research@vanderbilt.edu
Contact: Emily M Garland, PhD adc.research@vanderbilt.edu
United States
 
NCT00581477
David Robertson, MD, Vanderbilt University
030750, HL056693
Vanderbilt University
 
Principal Investigator: David Robertson, MD Vanderbilt University
Vanderbilt University
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP